Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...
As treatment options expand in chronic lymphocytic leukemia (CLL), the benefits and limitations of fixed-duration regimens in ...
First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trial Regimen offers another option for the ...
AbbVie seeks FDA approval for Venclexta and Calquence combination for untreated CLL, following positive AMPLIFY trial results. The combination regimen showed a 35% reduction in disease progression or ...
Pierluigi Porcu, MD, speaks to the considerations clinicians need to account for to balance cost, patient experience, and outcomes for those with chronic lymphocytic leukemia (CLL). As treatment ...
Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...
Error-corrected sequencing of non–B-cell fractions in CLL12/CLL14 detected CH in ~58% of CLL, with 35% meeting CHIP criteria. Cytotoxic regimens, especially chlorambucil-based therapy, were linked to ...
SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, reaffirms its position as the leader in chronic lymphocytic leukemia (CLL) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results